New Podcast: BTOG does … Tobacco Dependency in Lung Cancer. Dr Emma O’Dowd talks to Professor Sanjay Agrawal. Wherever you get your podcasts or listen online btog.org/btog-podcasts/ #LCSM #LungCancer

Sub-cut Nivolumab is go! www.gov.uk/government/n... #LCSM @btog.bsky.social #Mesothelioma

@btog.bsky.social #Nostaligia

Delighted to share that Debra our Chair has been elected President of Lung Cancer Europe. She says, “As LuCE’s first patient President, I’m honoured to build on Anne-Marie’s leadership & continue strengthening the voice of people affected by #lungcancer across Europe.” #LCSM

Only 45% of eligible ALK+ #lungcancer patients in England got targeted treatment. People well enough to benefit didn’t get the drugs they needed. This isn’t good enough. #LCSM www.lungcanceraudit.org.uk/wp-content/u...

FLAURA2 regimen now reimbursed. I have some questions. Who needs chemo? Everyone? Selected pts? Access to other therapies - assume Impower150 not available to patient who have had Chemo-Osi? Is chemo-Osi likely better than sequencing Osi-IMPOWER 150? Lung cancer keeps getting more complex!

Read the April roundup of top stories from all 15 NIHR ARCs across the country 👇 mailchi.mp/nihr/april-2... Incuding the latest research, resources, blogs, awards, events, training & much more Join here to get this monthly roundup sent directly to your inbox: tinyurl.com/ARCsnewsletter

Mr11 has gone to #Nando’s to celebrate last day of term with his mates… means I get to eat stuff he won’t! Boom! Winner, winner salmon dinner!!

Pondering posting this since yesterday…. Yet another PIP report request asking when my patient with advanced lung cancer with brain mets might expect to be better from brain mets… is it appropriate to suggest they refer themself for brain imaging? 😡🤬😡🤬😡🤬🤬🤬

New review on ADCs in #lungcancer “These are now being explored in other oncogene-driven subsets, including ALK…” Still early days—but could help when TKIs stop working. Worth watching #LCSM www.cancertreatmentreviews.com/article/S030...

Important & moving words from our amazing Fundraising Trustee Callum, who lost his mum to ALK+ #lungcancer last March. This September, he’s running 6 marathons in 6 days across 6 countries to raise global awareness for ALK+ lung cancer. #ALKpositive #LungCancerAwareness #LCSM

BTOG 2025 events for your diary ... BTOG/ @nlca-natcan.bsky.social State of the Nation Update Webinar – Thu 15 May ASCO Update Webinar June (date TBC) WCLC Update Webinar September (date TBC) continued...

It happens to be the 30 year anniversary of my Oxford Medical School graduation this year. This cartoon from the time of life predicted as a new NHS graduate hit the mark.

In 2021 I assumed my cough was from allergies & my chest pressure was work stress. It was stage 4 #lungcancer. An x-ray & biomarker testing saved my life. Had no idea that anyone can get lung cancer. 📺 interview from @younglungcancer.bsky.social 👉https://youtu.be/S50UEv81kS0?si=rixipm5FYbvOmpNx 🤍

@btog.bsky.social community, Assemble!

Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨 It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide! bit.ly/43JzN03 @christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social

Unfortunately, my NIH grant (Columbia P50 center grant subcontract) was one of the awards terminated. A stop work order has been issued. We’re 8 months into the project— a community engaged study to ⬆️ 🫁 ca & CVD screening in nyc. I know many others affected as well. Hoping for reversal/resolution 😕

On the 5th Anniversary of Covid, I’m thinking of all those who lost their lives, including my cousin Julie Omar (Nee Harris), whose only error was going to work… www.bbc.co.uk/news/uk-engl...

@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS #BTOG25

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

Graham Warren on smoking cessation in lung cancer pts. Extraordinary data: 🔺 $3.4bn cost of failed treatment if don’t quit 🔺 ⬇️ 45% mortality if quit 🔺Less frequent reminders more effective than more 🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit Sensational talk 🤯

Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25

@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

“We’re talking about people’s lives, not just pathways. If it was your life on the line you wouldn’t settle for 64 days of waiting.” Patient perspective on waits for genomic testing in #lungcancer at #BTOG25

@drsanjaypopat.bsky.social ! The OG!!! #BTOG25 @btog.bsky.social

Speed to diagnosis is key for ppl w #lungcancer- many of us are diagnosed at stage 4 when unwell. Great talk from Sandi Deans @nhsenglandldn.bsky.social Genomics at #BTOG25, illustrating the ideal pathway to reach the 14-day turnaround target in UK. Good to see ctDNA here #LCSM @btog.bsky.social

Magda Meissner on the Welsh ctDNA experience - an ‘in house’ solution assay wise and a huge amount of effort in validating and also learning to get more patients to test and more clinicians to genomic literacy #BTOG25

Debra Montague on ensuring the patient voice is not lost. The most important person in the room after all! We haven’t lost the patient voice but we all need to be better at listening! #BTOG25

Matthew Krebs on ctDNA and moving away from confirmatory tissue testing where an informative result is present. Key number 1% VAF for determining of non-actionable mutations are informative #BTOG25

High pan-immune inflammation calue (PIV) associated with poor outcome me in ALK+ve disease @oncolojo.bsky.social

Caught the most amazing sunrise en route to the #BTOG25 5km… there are some benefits to wandering the streets at 6:30am 🤣

Sandi Deans in delivering a 14 day genomics service, and the impact of the ctDNA pilots and roll out in potential time saving. CtDNA now pending addition to the Directory @BTOG25

Big news from #BTOG25 … next year’s event will be held in the beautiful city of Edinburgh 4-6 March 2026.

We’re sharing patient insights on ALK+ #lungcancer trtmt at #BTOG25. Alectinib had the most side effects, Brigatinib the least. 30-45% on Lorlatinib reported visual, cognitive, or mood effects. When considering side effects alone, 71% chose Lorlatinib over Alectinib. Real experiences matter. #LCSM

NLCA 2023. Captures genomics info for the first time. This is going to be crucial moving forwards #BTOG25

In 2018, with Tom Newsom-Davis, I wrote a chapter on novel immune check point targets for the ACP book ‘Problem Solving In Cancer Immunotherapy’. It’s fab to sit here and know my research wasn’t too far off and these targets now have drugs! Shobhit Baijal on ‘beyond PDL1/PD1 #BTOG25

Nicola Steele on the radical EGFRm arena - ADAURA-NEOADAURA-LAURA and a cheeky bit of PACIFIC. Targeted treatment sees gains across the board, and given PACIFIC data, LAURA a key trail. Needs desecration criteria to aid reimbursement? #BTOG25

Jan von der Thusen on the challenge of ADC biomarkers Biological validity: expression levels. What about tumoural heterogeneity? The impact of initial therapy on target antigen levels? #BTOG25

Prof Samreen Ahmed on ADCs and why they fail (or succeed - the utility of bystander functionality interesting) #BTOG25

DATO-DXd in EGFR interesting. 44% response rate in the pretreated group #BTOG25

Patrick Forde on ADCs - starting with TROP2 directed drugs - disappointing in the later line arena, against Docetaxel. A trend towards but not significant statistically. #BTOG25

The HER2 TKIs - EGFR TKIs not especially efficacious. First more selective HER2 TKIs - similar with high risk of grade 3 toxicity, aligned with what we saw with 1G and 2G EGFR TKIs. Zongertinib looking interest g from a response and TRAE point #BTOG25

Meenali Chitnis on HER2 as a target in lung cancer. We still have far to go in the uk… #BTOG25

Please do check out Roxane Chen’s (my iBSc student - a medical student) poster on pan-immune inflammation scoring and outcomes in ALK positive lung cancer. She worked so hard, and has been rewarded with the first abstract in the book, so no excuses not to engage, people! ❤️ No 1!! 🏅 #BTOG25

Really looking forwards to the genomics session. Debra is an amazing speaker and it will be interesting to really find out what matters!

On the DLR rail replacement bus service to City Airport! #BTOG2025 here I come! @btog.bsky.social

‼️ 1 day until #BTOG25 ‼️ Things to look forward to #12 Sandi Deans, Tuesday morning, on how to deliver genomics within a 2wk turnaround Vital for all of our patients, and a huge challenge. Sandi is Deputy Director of the @nhsenglandldn.bsky.social Genomics Unit

‼️ 2 days until #BTOG25 ‼️ Things to look forward to #4 The fun run! C’mon. You know you want to

I’m not sure what kind of 1980’s music mega mix voodoo is going on on @bbcradio2bot.bsky.social but it’s amazing!!! Mr 11 thinks I’ve lost the plot!!